Johnson & Johnson Says Its One-Dose Coronavirus Vaccine Was 66% Effective in Clinical Trial
The vaccine was 100% effective in preventing hospitalization and death from COVID-19.
Full Article
Johnson & Johnson Says Its One-Dose Coronavirus Vaccine Was 66% Effective in Clinical Trial
Motley Fool
0 shares
1 views
You might like
Related news coverage
Study: J&J COVID-19 Vaccine 72% Effective in U.S.
Newsy
Watch VideoAnother drugmaker is sharing the data that their COVID vaccine works. In clinical trials of more than 43,000 people,..
-
Single-shot Johnson & Johnson coronavirus vaccine found to be 66 per cent effective in global trial
SBS
-
Johnson & Johnson and Novavax COVID vaccines offer promising results
CBS News
-
Johnson & Johnson Single-Shot Coronavirus Vaccine Could Be Ready by June
Just Jared
-
Coronavirus | Novavax vaccine highly effective, but not against South Africa variant
Hindu
Advertisement
More coverage
As Coronavirus Rises Past Three Million, Africa Hopes For Vaccine – Analysis
Eurasia Review
With its large population and fragile health systems, Africa has recorded more than three million Covid-19 cases, still less deadly..
-
Novavax COVID-19 Vaccine 89.3% Effective In Phase 3 UK Trial
RTTNews
-
Novavax's COVID-19 vaccine shown to be nearly 90% effective in UK clinical trial, also provided immunity against new variants
USATODAY.com
-
Early Trials: Johnson & Johnson COVID Vaccine Prompts Immune Response
Newsy
-
NA Proactive news snapshot: GGX Gold, Bragg Gaming, Ideanomics, Victory Square Technologies, Genprex UPDATE …
Proactive Investors